EWA
AMED

EverSource Wealth Advisors’s Amedisys AMED Stock Holding History

EverSource Wealth Advisors’s Portfolio AMED Stock Details AMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-475
Closed -$46.7K – 4326
2025
Q2 		$46.7K Buy
475
+344
+263% +$32.5K ﹤0.01% 1662
2025
Q1 		$12.1K Buy
131
+21
+19% +$1.94K ﹤0.01% 1997
2024
Q4 		$9.99K Buy
110
+6
+6% +$551 ﹤0.01% 1992
2024
Q3 		$10K Buy
104
+71
+215% +$6.93K ﹤0.01% 1861
2024
Q2 		$3.24K Buy
33
+28
+560% +$2.6K ﹤0.01% 2381
2024
Q1 		$460 Sell
5
-6
-55% -$562 ﹤0.01% 2745
2023
Q4 		$1.05K Sell
11
-217
-95% -$20.3K ﹤0.01% 2389
2023
Q3 		$21.3K Buy
228
+137
+151% +$12.7K ﹤0.01% 1104
2023
Q2 		$8.32K Sell
91
-147
-62% -$12.1K ﹤0.01% 1526
2023
Q1 		$17.5K Sell
238
-6
-2% -$519 ﹤0.01% 1129
2022
Q4 		$20.4K Buy
+244
New +$22K ﹤0.01% 1065

Other funds holding AMED

Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
MCI
MRP Capital Investments Alpharetta, Georgia $115M AUM 48.08% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

EverSource Wealth Advisors's AMED Position: Q3 2025 in Review

EverSource Wealth Advisors sold out of Amedisys (AMED) in Q3 2025, closing a stake of 475 shares — an estimated $46.7K sold.

EverSource Wealth Advisors first reported a position in AMED in Q4 2022 and held it in 11 quarters. The position peaked at $46.7K in Q2 2025. 4 funds tracked by Wall St. Rank hold AMED as of Q3 2025.

  • EverSource Wealth Advisors reported no remaining Amedisys position as of Q3 2025 after selling out during the quarter.
  • EverSource Wealth Advisors sold 475 Amedisys shares in Q3 2025, an estimated $46.7K.
  • EverSource Wealth Advisors first reported a position in Amedisys in Q4 2022 and held it in 11 quarters.
  • EverSource Wealth Advisors's Amedisys position peaked at $46.7K in Q2 2025.
  • 4 funds tracked by Wall St. Rank held Amedisys as of Q3 2025.

Based on EverSource Wealth Advisors's 13F filing for Q3 2025, filed 10 Nov 2025.